Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys
Therefore, PKPD-L1<sup>Vac</sup> could be considered suitable for further complex toxicological studies and the way for its clinical evaluation in humans has been opened.
Authors
- Mónica Béquet‐Romero (ORCID: https://orcid.org/0000-0003-0351-857X)
- Alexei F. Licea-Navarro (ORCID: https://orcid.org/0000-0003-4022-7405)
- Olivia Cabanillas-Bernal (ORCID: https://orcid.org/0000-0002-0425-9699)
- Camila Canaan-Haden-Ayala (ORCID: https://orcid.org/0000-0002-7592-0579)
- Pedro Puente‐Pérez
- Jorge Castro-Velazco
- Rafael Martínez-Castillo
- Isabel González-Moya (ORCID: https://orcid.org/0000-0001-7633-4769)
- Marta Ayala‐Ávila (ORCID: https://orcid.org/0000-0003-4441-4953)
- Yunier Rodríguez‐Álvarez (ORCID: https://orcid.org/0000-0001-9428-5606)
- Yanelys Morera Díaz (ORCID: https://orcid.org/0000-0001-6051-5514)
- Javier Sánchez-Ramírez
- Marco A. De-León-Nava
Institutions
- Centro de Ingeniería Genética y Biotecnología (CU)
- Centro de Investigación Científica y de Educación Superior de Ensenada (MX)
Publication Details
- Journal
- Vaccines
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3390/vaccines13030296
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80